$65.98
1.32.01%
At Close: -
$66.00
0.020.03%
After Hours: 7:58 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Viking Therapeutics (NASDAQ:VKTX) Stock, Analyst Ratings, Price Targets, Forecasts
Viking Therapeutics Inc has a consensus price target of $79.86 based on the ratings of 14 analysts. The high is $138 issued by Oppenheimer on March 27, 2024. The low is $12 issued by SVB Leerink on April 28, 2022. The 3 most-recent analyst ratings were released by Raymond James, HC Wainwright & Co., and Morgan Stanley on July 25, 2024, July 25, 2024, and June 27, 2024, respectively. With an average price target of $104.33 between Raymond James, HC Wainwright & Co., and Morgan Stanley, there's an implied 58.08% upside for Viking Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Raymond James
HC Wainwright & Co.
Morgan Stanley
Truist Securities
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Viking Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | Buy Now | 78.79% | Raymond James | Steven Seedhouse | $116 → $118 | Maintains | Strong Buy | Get Alert |
| 07/25/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2024 | Buy Now | 59.09% | Morgan Stanley | Michael Ulz | → $105 | Initiates | → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 81.82% | Truist Securities | Joon Lee | $120 → $120 | Maintains | Buy | Get Alert |
| 06/04/2024 | Buy Now | — | Raymond James | Steven Seedhouse | — | Reiterates | → Strong Buy | Get Alert |
| 06/04/2024 | Buy Now | 81.82% | Maxim Group | Naz Rahman | $120 → $120 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 81.82% | Truist Securities | Joon Lee | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 75.76% | Raymond James | Steven Seedhouse | $115 → $116 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 109.09% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2024 | Buy Now | 109.09% | Oppenheimer | Jay Olson | $116 → $138 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 89.39% | BTIG | Justin Zelin | $100 → $125 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 81.82% | Maxim Group | Naz Rahman | → $120 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 21.21% | Stifel | Annabel Samimy | → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 51.52% | BTIG | Justin Zelin | $86 → $100 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 66.67% | Jefferies | Roger Song | → $110 | Initiates | → Buy | Get Alert |
| 02/29/2024 | Buy Now | 81.82% | Truist Securities | Joon Lee | $32 → $120 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 75.76% | Oppenheimer | Jay Olson | $46 → $116 | Maintains | Outperform | Get Alert |
| 02/27/2024 | Buy Now | 74.24% | Raymond James | Steven Seedhouse | $37 → $115 | Maintains | Outperform | Get Alert |
| 02/27/2024 | Buy Now | 36.36% | HC Wainwright & Co. | Joseph Pantginis | $33 → $90 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | -46.97% | Stifel | Annabel Samimy | $30 → $35 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | -24.24% | Maxim Group | Naz Rahman | $35 → $50 | Maintains | Buy | Get Alert |
| 12/04/2023 | Buy Now | -51.52% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2023 | Buy Now | -51.52% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | -54.55% | Stifel | Annabel Samimy | → $30 | Reiterates | → Buy | Get Alert |
| 07/27/2023 | Buy Now | -50% | HC Wainwright & Co. | Joseph Pantginis | → $33 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | -51.52% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | Buy Now | -51.52% | Roth MKM | Dylan Dupuis | → $32 | Assumes | → Buy | Get Alert |
| 05/17/2023 | Buy Now | -43.94% | Raymond James | Steven Seedhouse | $35 → $37 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | -39.39% | Oppenheimer | Jay Olson | $35 → $40 | Maintains | Outperform | Get Alert |
| 05/16/2023 | Buy Now | -54.55% | Stifel | Annabel Samimy | $25 → $30 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | -45.45% | BTIG | Justin Zelin | $31 → $36 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | -50% | HC Wainwright & Co. | Joseph Pantginis | → $33 | Reiterates | → Buy | Get Alert |
| 05/03/2023 | Buy Now | -63.64% | Roth MKM | Scott Henry | $19 → $24 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | -46.97% | Oppenheimer | Jay Olson | → $35 | Reiterates | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | -50% | HC Wainwright & Co. | Joseph Pantginis | $21 → $33 | Maintains | Buy | Get Alert |
| 04/25/2023 | Buy Now | -46.97% | Oppenheimer | Jay Olson | $30 → $35 | Maintains | Outperform | Get Alert |
| 03/29/2023 | Buy Now | -71.21% | Roth MKM | Matt Koranda | $15 → $19 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | -62.12% | Maxim Group | Anthony Vendetti | $15 → $25 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | -51.52% | Truist Securities | Joon Lee | $28 → $32 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | -46.97% | Raymond James | Steven Seedhouse | $12 → $35 | Maintains | Outperform | Get Alert |
| 03/29/2023 | Buy Now | -53.03% | BTIG | Justin Zelin | $20 → $31 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | -54.55% | Oppenheimer | Jay Olson | $20 → $30 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | -62.12% | Stifel | Annabel Samimy | $22 → $25 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | -66.67% | Stifel | Annabel Samimy | → $22 | Initiates | → Buy | Get Alert |
| 02/09/2023 | Buy Now | -81.82% | Raymond James | Steven Seedhouse | $11 → $12 | Maintains | Outperform | Get Alert |
| 02/09/2023 | Buy Now | -68.18% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 12/20/2022 | Buy Now | -77.27% | Maxim Group | Naz Rahman | $10 → $15 | Maintains | Buy | Get Alert |
| 10/27/2022 | Buy Now | -83.33% | Raymond James | Steven Seedhouse | $10 → $11 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | -81.82% | SVB Leerink | Thomas Smith | $18 → $12 | Maintains | Outperform | Get Alert |
| 02/10/2022 | Buy Now | -84.85% | Raymond James | Steven Seedhouse | $13 → $10 | Maintains | Outperform | Get Alert |
| 07/29/2021 | Buy Now | -80.3% | Raymond James | Steven Seedhouse | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Viking Therapeutics (VKTX) stock?
The latest price target for Viking Therapeutics (NASDAQ:VKTX) was reported by Raymond James on July 25, 2024. The analyst firm set a price target for $118.00 expecting VKTX to rise to within 12 months (a possible 78.79% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viking Therapeutics (VKTX)?
The latest analyst rating for Viking Therapeutics (NASDAQ:VKTX) was provided by Raymond James, and Viking Therapeutics maintained their strong buy rating.
When was the last upgrade for Viking Therapeutics (VKTX)?
The last upgrade for Viking Therapeutics Inc happened on May 16, 2024 when Raymond James raised their price target to $116. Raymond James previously had an outperform for Viking Therapeutics Inc.
When was the last downgrade for Viking Therapeutics (VKTX)?
There is no last downgrade for Viking Therapeutics.
When is the next analyst rating going to be posted or updated for Viking Therapeutics (VKTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viking Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viking Therapeutics was filed on July 25, 2024 so you should expect the next rating to be made available sometime around July 25, 2025.
Is the Analyst Rating Viking Therapeutics (VKTX) correct?
While ratings are subjective and will change, the latest Viking Therapeutics (VKTX) rating was a maintained with a price target of $116.00 to $118.00. The current price Viking Therapeutics (VKTX) is trading at is $66.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.